VBI Vaccines
http://www.vbivaccines.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From VBI Vaccines
Big Pharma Pacts Benefit From Reduced HBV Biologics Competition
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
EMA Thumbs Up For Idorsia’s Insomnia Drug And Immunocore’s Uveal Melanoma Treatment
An insomnia drug to improve daytime functioning, a treatment for a rare type of eye cancer, and an oral migraine drug for both acute and preventive treatment are among 13 new products recommended for pan-EU approval.
Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
CDC Panel Stops Shy Of Universal Adult Hepatitis B Vaccine Recommendation
ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Variation Biotechnologies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice